A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.


Updates from The Motley Fool

Latest updates on PDL BioPharma from Fool.com.  The Fool has written over 200 articles on PDL BioPharma.
3 Horrible Stocks for Retirees

These three stocks offer temping dividend yields, but retirees would do well to avoid them.

3 Tempting Stocks to Avoid

Are these stocks value buys or value traps? Only time will tell, but we can offer some insight.

3 Big Risks Biotech Stocks Face

We discuss what trial failure, commercial failure, and patent expiration at Celldex, MannKind, an...



Stock Performance

View Interactive PDLI Charts
Sponsored by

Key Data Points

Primary metrics and data points about PDL BioPharma.
Current Price: $2.39
Prev Close: $2.34
Open: $2.33
Bid: $2.28
Ask: $2.39
Day's Range: $2.33 - $2.39
52wk Range: $1.93 - $3.77
Volume: 903,999
Avg Vol 1,705,939
Market Cap: $385M
P/E (ttm): 26.00
EPS (ttm): $0.09
Div & Yield: $0.20 (0.0%)

Company Rating

What our community thinks about PDL BioPharma.
CAPS Rating 3 out of 5
 
835 Outperform
45 Underperform
CAPS All Stars
 
153 Outperform
12 Underperform

How do you think PDL BioPharma will perform against the market?



You pick for PDL BioPharma is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John P. McLaughlin, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for PDL BioPharma.

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers